Verrica Pharmaceuticals Inc. Quarterly Debt-to-equity in % from Q1 2019 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Verrica Pharmaceuticals Inc. quarterly Debt-to-equity history and growth rate from Q1 2019 to Q2 2024.
  • Verrica Pharmaceuticals Inc. Debt-to-equity for the quarter ending June 30, 2024 was 491 %, a 5019% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 491 +481 +5019% Jun 30, 2024
Q1 2024 158 +122 +338% Mar 31, 2024
Q4 2023 69.8 -11.1 -13.7% Dec 31, 2023
Q3 2023 34.6 -87.3 -71.6% Sep 30, 2023
Q2 2023 9.59 -154 -94.1% Jun 30, 2023
Q1 2023 36.1 -88.7 -71.1% Mar 31, 2023
Q4 2022 80.9 -19.7 -19.6% Dec 31, 2022
Q3 2022 122 +24.9 +25.6% Sep 30, 2022
Q2 2022 164 +69.8 +74.2% Jun 30, 2022
Q1 2022 125 +33.3 +36.4% Mar 31, 2022
Q4 2021 101 +11.2 +12.5% Dec 31, 2021
Q3 2021 97 +39.3 +68.2% Sep 30, 2021
Q2 2021 94.1 +59.1 +169% Jun 30, 2021
Q1 2021 91.5 +73 +394% Mar 31, 2021
Q4 2020 89.4 +84.2 +1615% Dec 31, 2020
Q3 2020 57.7 +53.2 +1174% Sep 30, 2020
Q2 2020 34.9 +31.3 +861% Jun 30, 2020
Q1 2020 18.5 +15.5 +509% Mar 31, 2020
Q4 2019 5.22 Dec 31, 2019
Q3 2019 4.53 Sep 30, 2019
Q2 2019 3.63 Jun 30, 2019
Q1 2019 3.05 Mar 31, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.